Back | Next |
home / stock / aeri / aeri message board
Subject | By | Source | When |
---|---|---|---|
They are raising 75 mil more and going | Johnny_C | investorshub | 12/19/2017 2:03:50 PM |
Seems like Buyout is the only option now. | jones99 | investorshub | 12/19/2017 6:28:30 AM |
WOW... what timimg.. $AERI halted and drug approved | Johnny_C | investorshub | 12/18/2017 9:25:17 PM |
Back in - still concerned about | Johnny_C | investorshub | 12/18/2017 6:14:43 PM |
Just a few months to go for the | Johnny_C | investorshub | 11/19/2017 3:01:52 PM |
Analysts now calling up to 80. Might | Johnny_C | investorshub | 10/25/2017 8:48:47 PM |
Hopefully approved without a label. | Johnny_C | investorshub | 10/16/2017 3:34:57 PM |
Upon reading the one no vote is very | Johnny_C | investorshub | 10/13/2017 5:38:14 PM |
Oops. Sold to soon. Great news. | Johnny_C | investorshub | 10/13/2017 5:05:18 PM |
Aeri halted. Could be good news, seems | Johnny_C | investorshub | 10/13/2017 11:58:47 AM |
In since $11.00. Time to say goodbye | Johnny_C | investorshub | 10/11/2017 3:02:26 PM |
Meeting is on, my reading is drug is | Johnny_C | investorshub | 10/11/2017 1:55:42 PM |
Aeri flying. Data so good no need for | Johnny_C | investorshub | 10/11/2017 1:31:01 PM |
Good day for Aeri. Maybe profit | Johnny_C | investorshub | 10/10/2017 8:56:31 PM |
Big day Friday. Was a steal | Johnny_C | investorshub | 10/09/2017 8:18:04 PM |
The FDA's Dermatologic and Ophthalmic Drugs Advisory Committee | realfast95 | investorshub | 10/03/2017 7:01:06 PM |
Decent correction. Upcoming FDA will be huge. | Johnny_C | investorshub | 09/29/2017 8:03:58 PM |
Hit new high this week. Not a bad | Johnny_C | investorshub | 09/22/2017 7:45:50 PM |
Aeri creeping back towards ALL TIME highs... Winner Winner! | Johnny_C | investorshub | 07/12/2017 4:25:52 PM |
Still holding, bought at 9 sold at 32. | Johnny_C | investorshub | 07/07/2017 8:52:31 PM |
News, Short Squeeze, Breakout and More Instantly...
Aerie Pharmaceuticals Inc. Company Name:
AERI Stock Symbol:
NASDAQ Market:
Aerie Pharmaceuticals Inc. Website:
Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Al...
Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceut...
NEW YORK, NY / ACCESSWIRE / October 30, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Altra Industrial Motion Corp. (NA...